drugset / Trial / NCT07121777
Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, single-site, dose-escalation study in up to 18 participants with treatment of Refractory Autoimmune Diseases. This study aims to evaluate the safety and efficacy of the treatment with an Anti- CD19/BCMA CAR gene vector injection
Timeline
- Start
- 2025-08-25
- Primary completion
- 2029-08-31
- Completion
- 2029-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-CD19/BCMA CAR-T cells | Cell therapy | 1e+06 unknown | Intravenous |
| Subject | anti-CD19/BCMA CAR-T cells | Cell therapy | 4e+06 unknown | Intravenous |